Exact Sciences Launches the Oncodetect ™ Molecular Residual Disease Test
The Oncodetect test delivers clear "Detected' or 'Not Detected' results, accompanied by quantitative data to help support adjuvant therapy decisions, evaluate treatment response, and monitor cancer recurrence. Notably, patients who test positive for ctDNA with the Oncodetect test during surveillance are 50 times more likely to experience cancer recurrence than those with negative results 1. Highly sensitive and personalized, the test tracks up to 200 tumor-specific variants and identifies even trace amounts of ctDNA—down to 1 ctDNA molecule in 20,000 cfDNA ‡ molecules. This sensitivity enables earlier detection of CRC recurrence compared to imaging alone 1,2.
"Exact Sciences is transforming cancer care by delivering tests that provide the clarity patients and physicians need to make confident decisions," said Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences. "After surgery and definitive therapy, such as chemotherapy or radiation, the risk for cancer recurrence remains a major concern. Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care.'
Backed by robust clinical validation, including data from the Alpha-CORRECT study—one of the longest-followed MRD cohorts for CRC recurrence with nearly five years of follow-up—the Oncodetect test enhances understanding of cancer recurrence and helps support timely, personalized treatment decisions. Exact Sciences is actively working with Medicare to secure reimbursement for the test, ensuring broad patient access nationwide. The company is also advancing clinical and analytical validation studies across multiple solid tumors, supported by strategic partnerships for multi-cancer evidence generation.
'Exact Sciences is a longtime trusted partner in addressing the critical unmet needs in colorectal cancer care, ensuring patients have the insights they need to navigate treatment with confidence,' said Vanessa Ghigliotty, Certified Patient Navigator & Chair, Patient Advisory Board, GI Cancers Alliance §. 'For those facing the uncertainty of recurrence, tumor-informed MRD tests like the Oncodetect test can provide clear, timely answers—empowering patients to take an active role in their care and receive the right treatment at the right time for better outcomes.'
The Oncodetect test builds on 20 years of genomic testing excellence established by the Oncotype DX Breast Recurrence Score ® test. Integrated into a world-class digital experience, supported by the ExactNexus™ technology platform, the Oncodetect test can be ordered with other Exact Sciences tests, including OncoExTra ® (comprehensive genomic profiling) and Riskguard® (hereditary cancer testing). With more than 3 million American patients 3 eligible for MRD testing, Exact Sciences is well-positioned to shape the future of personalized care.
The Oncodetect test is now available. For more information, visit www.oncodetect.com
* Circulating tumor DNA
† The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test's clinical validation.
‡ Cell-free DNA
§ Ghigliotty attended the March 2025 Cologuard Classic through a grant from Exact Sciences to the GI Cancers Alliance, which has also received prior funding from the company.
References
Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology.
Santonja et al 2023 EMBO (https://www.embopress.org/doi/full/10.15252/emmm.202216505)
Data source on file
Internal product profile of the Oncodetect test
About the Oncodetect test
Developed by Exact Sciences, the Oncodetect test is a tumor-informed molecular residual disease (MRD) test designed to provide a personalized approach to detecting and monitoring residual cancer in patients with solid tumors. By leveraging the company's expertise in whole exome sequencing, the Oncodetect test analyzes circulating tumor DNA (ctDNA) shed into the bloodstream by tumors, offering critical insights into changes in ctDNA levels over time. This quantitative assessment of ctDNA (measured as MTM/mL) helps healthcare providers better understand a patient's MRD status and make informed treatment decisions 4.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
Oncodetect, Oncotype, Oncotype DX Breast Recurrence Score, and OncoExTra are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences. Exact Sciences, Cologuard, and Riskguard are trademarks of Exact Sciences Corporation. Oncodetect, Cologuard, Riskguard, and OncoExTra are only available in the United States.
Forward-Looking Statement
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements regarding our expectations for the commercialization of the Oncodetect test and the performance of the Oncodetect test in a commercial setting. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Develop Health Raises $14.3M to Automate Prior Authorization and Medication Access Using GenAI
SAN FRANCISCO--(BUSINESS WIRE)-- Develop Health, an EHR-integrated benefits‑verification and prior‑authorization platform, today announced a $14.3 million Series A led by Wing Venture Capital, with participation from Afore Capital, J Ventures, and South Park Commons. The round brings the company's total funding to $17.6 million. Built with over a dozen purpose-built large language model pipelines, Develop Health is the first medication access platform fully architected around GenAI. Its EHR-integrated platform plugs into virtual care workflows to verify insurance coverage in real time, generate and submit the correct prior authorization package, follow up and track status continuously, and return structured data back into the provider's system, all without manual effort from care teams. Founded by Mel van Londen and Benjamin Easton, Develop Health is tackling a growing bottleneck in healthcare: the administrative complexity that delays access to necessary medications. Before Develop Health, the founders held roles at provider-facing healthcare startups Canvas Medical and Rupa Health, where they saw how poor communication and data fidelity between providers and payers led to delayed treatment, lost revenue, and worse outcomes for patients. 'We believe providers should be able to make care decisions with full visibility into a patient's plan, because a prescription that isn't affordable or accessible is no prescription at all,' said Mel van Londen, co-founder and CEO of Develop Health. 'We're building healthcare's agentic clearinghouse, starting with medication access and designing infrastructure that meets both payers and providers where they are.' The new funding will fuel Develop Health's expansion beyond its core work helping digital health companies navigate the pharmacy benefit space—spanning GLP-1s and treatments across addiction, neurology, dermatology, and psychiatry—into the medical benefit market. The company will also deepen its integrations with both EHRs and PBMs, streamlining and scaling the link between prescribing and coverage, and extend its reach into traditional providers outside of digital health. 'Develop Health is solving one of the most frustrating pain points in healthcare – getting patients the medications they need without weeks of paperwork and endless back-and-forth,' said Sara Choi, Partner at Wing Venture Capital. 'They've built a system that puts GenAI to work in one of the industry's most critical, overlooked workflows. Develop Health is positioned to become essential infrastructure for any provider dealing with medication access complexity. ' Today, Develop Health helps providers reduce churn, set clearer patient expectations, and streamline access to care. The platform reduces form completion time by over 80% and increases approval rates, improving both provider efficiency and patient experience. In just three months, the company has grown significantly and is on track to helping over 1 million patients access their medications by the end of this year. That traction has been driven by Develop Health's exceptional team of engineers, including Jack Collins, Juan de Urtubey, and Zygimantas Koncius, whose technical excellence has made the platform possible. About Develop Health Develop Health's mission is to empower providers by eliminating the friction of prior authorization and improving visibility into plan benefits—freeing up capacity to deliver truly high-quality patient care. At its core, Develop Health is healthcare's agentic clearinghouse, beginning with medication access. Today, the platform supports hundreds of thousands of patients each month in getting the treatments they need—while reducing administrative work related to medication access by 83%. Learn more at
Associated Press
an hour ago
- Associated Press
AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States
Jupiter, FL August 20, 2025 --( )-- AcCELLerated Biologics, LLC, a leading distributor of regenerative medicine technologies, today announced an exclusive agreement with IPG Medical Corporation, a wholly owned subsidiary of IPG Photonics Corporation, to distribute the RegenaLase™ Laser System throughout the United States. This new dual-wavelength laser platform is engineered to treat musculoskeletal soft tissue, including meniscus cartilage and inflammation. The RegenaLase system features two advanced laser modalities: 1550 nm erbium fiber laser for minimally invasive cartilage surgery 980 nm diode laser for non-invasive photobiomodulation therapy This dual functionality enables physicians to provide both in-office pain relief and advanced cartilage treatment — all from a single, compact, and versatile device. 'This partnership with IPG Medical marks a major milestone in regenerative medicine,' said Steve Whyte, CEO and Founder of AcCELLerated Biologics. The 'RegenaLase system merges laser innovation with non-invasive phototherapy, giving physicians powerful tools to reduce pain and restore cartilage—without the complications of traditional surgery. At AcCELLerated Biologics, we remain committed to being first to market with cutting-edge solutions that empower our physicians to deliver exceptional care to their patients.' 'I recently attended a cadaver training course at RMTI in Jupiter, Florida, to learn in detail how the RegenaLase Laser can treat musculoskeletal pathologies. This laser technology is poised to be a game changer,' said Joshua G. Hackel, MD, FAAFP, RMSK, CAQSM, Sports Medicine Specialist at the Andrews Institute for Orthopaedics and Sports Medicine. 'We are looking forward to conducting a prospective study utilizing the RegenaLase Laser System to treat knee osteoarthritis at the Andrews Research and Education Foundation in Gulf Breeze, Florida.' 'I have been fortunate in my career to be involved in some groundbreaking technology and techniques. It has allowed me to help many patients heal from their injuries,' said Michael A. Scarpone, D.O. Scarpone Sports Regenerative, Steubenville, Ohio. 'The RegenaLase laser is one of those technologies that has the potential to help a great many patients with knee osteoarthritis and beyond. I am excited to be participating in this project — past, present, and future.' Clinical studies have demonstrated the effectiveness of RegenaLase when paired with optional biologic adjuncts such as Platelet-Rich Plasma (PRP), adipose tissue, and bone marrow aspirate. Patients have shown significant reductions in pain and measurable improvements in joint function. Designed with ergonomics and flexibility in mind, the system is well-suited for both surgical suites and office-based settings, enabling highly personalized treatment protocols, based on delivering multiple, separated microscopic columns of coagulation to the target tissue. 'We're excited to partner with AcCELLerated Biologics to expand access to the RegenaLase system across the United States,' said Alexander Vybornov, IPG Medical Sr. Director of Partnerships & Commercialization. 'With our expertise in laser innovation and AcCELLerated Biologics' strong clinical support and distribution network, more physicians will be empowered to adopt this advanced laser therapy for pain management and advanced musculoskeletal tissue treatment.' The RegenaLase system is FDA-cleared for coagulation of soft tissue including meniscus cartilage, and temporary relief of pain via tissue heating. About AcCELLerated Biologics, LLC AcCELLerated Biologics is a premier distributor of regenerative medicine devices and biologics, dedicated to equipping physicians with the most advanced technologies to improve patient outcomes. Learn More: Media Contact: Sharon Bruneau [email protected] Contact Information: AcCELLerated Biologics Sharon Bruneau +1 (407) 230-3290 Contact via Email Read the full story here: AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States Press Release Distributed by
Yahoo
2 hours ago
- Yahoo
Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership
Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company's non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. A closeup of a vial of the biotechnology company's vaccines. Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and Matrix-M adjuvant technology. The Maryland-based company has an approved COVID-19 vaccine, Nuvaxovid, which is being commercialized globally through partnerships, including a major agreement with Sanofi. Currently, the company is expanding its product reach for emerging infectious disease prevention. On May 19, 2025, Novavax, Inc. (NASDAQ:NVAX) announced that it had received U.S. FDA Biologics License Application (BLA) approval for Nuvaxovid™, a recombinant protein-based, non-mRNA COVID-19 vaccine. The BLA approval triggered a $175 million milestone payment from Sanofi. Later, for select markets, Novavax, Inc. (NASDAQ:NVAX) has completed the transition of Nuvaxovid™ commercial leadership to Sanofi for the 2025-2026 COVID-19 vaccination season. By Q4 2025, the marketing authorization transfers to Sanofi for the U.S. and EU markets will be completed, which will result in an additional $50 million in combined milestones. Additionally, in June 2025, initial cohort data from a Phase 3 trial for Novavax's COVID-19-Influenza-Combination (CIC) and stand-alone influenza vaccine candidates showed significant immune responses, with T-cell responses numerically higher than the comparator Fluzone HD arm. With the results suggesting increased duration of protection, the company is discussing potential partnerships for these late-stage assets. Novavax, Inc. (NASDAQ:NVAX)'s 29.12% short float signals heavy bearish sentiment. With it, the company is up on the stage for a sharp rebound with slight positive market sentiment shifts. While we acknowledge the potential of NVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
